IPO Price Range: ₹93 - 97
Min Investment
₹1,16,400
IPO Size
₹43 Cr
IPO Status
Quantity in 1 Lot
1200
Max Bid allowed
1
Listing Exchange
NSE
Bid Opening Date | 15 May 2024 |
Bid Closing Date | 17 May 2024 |
Allotment Date | 21 May 2024 |
Issue Size | ₹43.16Cr |
Quantity in 1 lot | 1200 |
Multi-product capability.
Revenue from Government institutions.
Product Portfolio.
Research and Development.
Quality assurance.
Experienced Promoter and management team.
Supply Chain Efficiency.
The company has certain outstanding litigation against it, an adverse outcome of which may adversely affect its business, reputation and results of operations.
Any manufacturing or quality control problems may disrupt its business operations, damage the company reputation for high quality production and expose it to potential litigation or other liabilities, which would negatively impact its business, prospects, cash flows, results of operations and financial condition.
The Company is reliant on the demand from the pharmaceutical industry for a significant portion of its revenue. Any downturn in the pharmaceutical industry or an inability to increase or effectively manage its sales could have an adverse impact on the Companys business and results of operations.
The products that the company commercialize may not perform as expected which could adversely affect its business, financial condition and results of operations.
Any manufacturing or quality control problems may damage its reputation for high quality products and expose the company to litigation or other liabilities, which could adversely affect its financial results.
The availability of counterfeit drugs, such as drugs passed off by others as its products, could adversely affect the company goodwill and results of operations.
Its business is dependent and will continue to depend on the companys manufacturing facility, and the company is subject to certain risks in its manufacturing process. Any slowdown or shutdown in the company manufacturing operations or strikes, work stoppages or increased wage demands by its employees that could interfere with the company operations could have an adverse effect on its business, financial condition and results of operations.
Its existing manufacturing facility are concentrated in a single region i.e., Pithampur, Indore, Madhya Pradesh and the inability to operate and grow its business in this particular region may have an adverse effect on the company business, financial condition, results of operations, cash flows and future business prospects.
The company highly depends on its major raw materials on many of the suppliers who help it procure the same. The Company has not entered into long-term agreements with its suppliers for supply of raw materials. In the event the company is unable to procure adequate amounts of raw materials, at competitive prices its business, results of operations and financial condition may be adversely affected.
Too much concentration of its Business is from sale to government which may impact the companys Business.
Investors | Holdings % |
Anil Kumar Sabarwal | 85.17% |
Tejaswini Sabarwal | 3.41% |
Organisation | Quest Laboratories Ltd |
Headquarters | Dhar |
Industry | Pharmaceuticals |